Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Cost of illness from occupational hand eczema in Germany.

Diepgen TL, Scheidt R, Weisshaar E, John SM, Hieke K.

Contact Dermatitis. 2013 Aug;69(2):99-106. doi: 10.1111/cod.12038.

PMID:
23869729
2.

Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany.

Augustin M, Kuessner D, Purwins S, Hieke K, Posthumus J, Diepgen TL.

Br J Dermatol. 2011 Oct;165(4):845-51. doi: 10.1111/j.1365-2133.2011.10427.x.

PMID:
21623744
3.

Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates.

Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P.

J Hosp Infect. 2009 Jun;72(2):97-103. doi: 10.1016/j.jhin.2008.12.012. Epub 2009 Feb 25. Review.

PMID:
19246122
4.

Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.

Drugs Aging. 2008;25(3):255-68.

PMID:
18331076
5.

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson P.

Value Health. 2008 Sep-Oct;11(5):791-9. doi: 10.1111/j.1524-4733.2007.00302.x. Epub 2008 Jan 11.

6.

Anxiety and depression prevalence rates in age-related macular degeneration.

Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K, Berdeaux G.

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1498-503.

PMID:
17389477
7.

Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.

Pharmacoeconomics. 2006;24(2):193-205.

PMID:
16460138
8.

Costs of treatment of colorectal cancer in different settings in Germany.

Hieke K, Kleeberg UR, Stauch M, Grothey A.

Eur J Health Econ. 2004 Oct;5(3):270-3.

PMID:
15714348
9.
10.

Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine.

Herold M, Hieke K.

Eur J Health Econ. 2002;3(3):166-72.

PMID:
15609141
11.
12.
13.

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group.

Eur J Cancer. 2001 Mar;37(5):597-604.

PMID:
11290435
14.

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.

Lafuma A, Dreno B, Delaunay M, Emery C, Fagnani F, Hieke K, Bonerandi JJ, Grob JJ; French Cooperative Group on Melanoma.

Eur J Cancer. 2001 Feb;37(3):369-75.

PMID:
11239759
15.

The costs of rheumatoid arthritis: an international long-term view.

Pugner KM, Scott DI, Holmes JW, Hieke K.

Semin Arthritis Rheum. 2000 Apr;29(5):305-20. Review.

PMID:
10805355
16.

The links between joint damage and disability in rheumatoid arthritis.

Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K.

Rheumatology (Oxford). 2000 Feb;39(2):122-32. Review.

PMID:
10725061
17.

Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

Sweetenham J, Hieke K, Kerrigan M, Howard P, Smartt PF, McIntyre AM, Townshend S.

Br J Haematol. 1999 Jul;106(1):47-54.

PMID:
10444162
18.

Dorsal dislocation of four metacarpophalangeal joints.

Ferguson DB, Moore G, Hieke KA.

Ann Emerg Med. 1989 Feb;18(2):204-6.

PMID:
2916788

Supplemental Content

Support Center